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Summary
Background Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce 
aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on 
the rate of aortic dilatation in children and adults with Marfan syndrome.
Methods We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 
6–40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 
75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as 
tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All 
images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic 
root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794.
Findings Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to 
irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years 
(IQR 12–28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were 
taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo 
group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan 
group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of –0·22 mm 
per year (–0·41 to –0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in 
means –0·10 per year, 95% CI –0·19 to –0·01, p=0·035). Irbesartan was well tolerated with no observed differences in 
rates of serious adverse events.
Interpretation Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults 
with Marfan syndrome and could reduce the incidence of aortic complications.
Funding British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Marfan syndrome is a dominantly inherited disorder 
of connective tissue caused by mutations in the gene 
that encodes fibrillin-1.1 Cardiovascular complications, 
including aortic root dilatation, dissection, and rupture, 
are the leading cause of morbidity and mortality.2 
β blockers have been advocated to reduce the rate of 
aortic root dilatation in people with Marfan syndrome.3,4 
Experimental models of Marfan syndrome suggest that 
angiotensin-II type 1 receptor blockers (ARBs) can alter 
biological pathways, including excessive TGF-β signalling, 
that might contribute to the pathogenesis of aortic 
compli cations,5–8 a finding that is supported by obser-
vational data in clinical studies.9 Randomised trials in 
Marfan syndrome have compared the effects of the 
ARB losartan with either β blockers or control (where 
standard medical therapy could include β blockers) 
on aortic dilatation10–15 without clear evidence of benefit. 
Other ARBs, such as irbesartan, might have greater 
bioavailability and a longer half-life than losartan with 
more potent antihypertensive effects. We aimed to 
determine the effects of the ARB irbesartan on the rate of 
aortic dilatation in children and adults with Marfan 
syndrome.
Methods
Study design and participants
The design and methods for the Aortic Irbesartan Marfan 
Study (AIMS) study have previously been reported.16 
Briefly, AIMS was an investigator-led, placebo-controlled, 
double-blind randomised trial done at 22 centres with 
experience of managing Marfan Syndrome in the UK. 
The study protocol was approved by the UK National 
Research Ethics Committee, participating institutions, 
and relevant regulatory authorities. All participants, or 
their legal guardians in the case of children, provided 
written informed consent. The study complies with the 
principles of the Declaration of Helsinki.
Individuals were eligible for inclusion if they were aged 
between 6 and 40 years and had clinically confirmed 
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Marfan syndrome using the revised Ghent diagnostic 
criteria17 and an aortic Z score of more than zero on 
baseline echocardiography. Individuals were excluded 
if they had undergone cardiac or aortic surgery or if 
this was planned, an aortic diameter of at least 4·5 cm, 
haemodynamically severe valve disease, a clear thera-
peutic indication or contraindication for ARB, or heart 
failure or they were pregnant. Individuals with potential 
for pregnancy could be enrolled if they were using a 
reliable means of contraception. Participants continued 
all their routinely indicated treatments. β-blocker use 
was not mandated by this protocol and was used at the 
discretion of the treating physician.
Randomisation and masking
To ensure tolerability, all participants initially received 
open-label irbesartan 75 mg once daily for 4 weeks 
before randomisation. Participants were then randomly 
assigned, using a web-based system, 1:1 to irbesartan 
150 mg once daily for 4 weeks, titrated up to 300 mg once 
daily if tolerated and weight was more than 50 kg, or 
matching placebo for up to 5 years. The randomisation 
sequence was generated with randomly varying block 
sizes of 2 or 4 and stratified by centre, participant’s age 
and concurrent β-blocker use. Irbesartan and matching 
placebo were provided, in bulk, by Sanofi (Reading, UK) 
and drug packaging, storage and supply by Brecon 
Pharmaceuticals (Hay-on-Wye, UK).
Procedures
At entry to the trial, before the open-label run-in phase, 
each participant had height, weight, blood pressure, heart 
rate, baseline electrocardiograph, current medication, 
and renal function studies recorded. If patients tolerated 
study medication and were willing to proceed with the 
study, full blood count and renal function were measured 
at baseline (at the time of randomisation), 1 month after 
entering the trial, and annually thereafter. In patients 
who provided consent, samples for fibrillin-1 mutation 
analysis were obtained if not taken already.
Transthoracic echocardiograms were acquired on 
an annual basis by experienced echocardiographers, 
according to a standardised research protocol and training 
Research in context
Evidence before this study
The routine use of angiotensin receptor blockers to 
reduce aortic dilatation in Marfan syndrome has been 
controversial. Literature searches using PubMed (key words 
“Marfan syndrome“, “randomised“, and “angiotensin receptor 
blocker“) with no language or date restrictions (last search 
June 20, 2018) and discussion with other researchers were 
undertaken to identify all randomised controlled trials of 
angiotensin receptor blockers in Marfan syndrome. The largest 
randomised trial tested losartan against β blockers with 
similar effects on aortic dilatation, and the other 
two larger trials tested losartan against control with 
conflicting results. No trials of irbesartan in Marfan syndrome 
have been done.
Added value of this study
This AIMS trial shows that routine use of the angiotensin 
receptor blocker irbesartan was well tolerated and is associated 
with lower rates of aortic dilatation in children and young 
adults with Marfan syndrome compared with placebo. These 
results help to inform clinicians and patients about the use of 
irbesartan in Marfan syndrome.
Implications of all the available evidence
The results of the AIMS trial add to our knowledge of the effects 
of angiotensin receptor blockers in reducing the rate of aortic 
dilatation compared to placebo. Evidence suggests that this is a 
class effect and an individual patient data meta-analysis is in 
progress.
Figure 1: Study profile
*These adverse events were not serious. †Four did not attend, four withdrew consent, three non-compliance to 
medication, and two investigator decisions. ‡Nine did not attend, five withdrew consent, five non-compliance 
to medication, three investigator decisions, and three were ineligible.
206 patients received open-label irbesartan
192 randomly assigned
88 assigned to placebo 104 assigned to irbesartan
87 received initial dose
88 had baseline echo
104 received initial dose
104 had baseline echo
88 included in the final analysis 104 included in the final analysis
14 not randomly assigned
 7 adverse events*
 4 did not give consent
 1 did not attend clinic appointment
 1 with aortic root diameter too large
 1 non-compliance to medication
13 withdrew†
 3 in year 1
 3 in year 2
 5 in year 3
 1 in year 4
 1 in year 5
 6 discontinued treatment but remained 
  in follow-up
 1 in year 1
 1 in year 2
 3 in year 3
 0 in year 4
 1 in year 5
25 withdrew‡
 10 in year 1
 6 in year 2
 7 in year 3
 1 in year 4
 1 in year 5
 11 discontinued treatment but remained 
  in follow-up
         1 in year 1
         2 in year 2
         1 in year 3
       4 in year 4
         3 in year 5
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provided by the core echocardiography laboratory, inc-
luding assessment of inter-observer and intra-observer 
variability. Each echocardiogram was transferred in 
DICOM format to the core echocardiography laboratory 
at the John Radcliffe Hospital, University of Oxford, 
Oxford, where a single experienced investigator (XYJ) 
supervised the overall image analysis process and 
interpretation for the primary outcome data. The core 
echocardiography laboratory was blinded to study drug 
allocation to eliminate reading bias in echo measurement. 
Strict quality control processes were applied during the 
analysis according to the guidelines from the American 
Society of Echocardiography.18 From the parasternal 
long-axis view, aortic root diameter was measured using 
inner-edge to inner-edge technique during peak systole 
at the level of the sinus of Valsalva with the tip of the 
open cusps at ninety degrees to the direction of flow 
(primary endpoint; appendix p 9) and also at end diastole. 
Additional aortic diameter measure ments were made 
and will be reported separately. To adjust for somatic 
growth, aortic Z score was calculated based on aortic 
sinus diameter and body surface area as previously 
described by Devereux and colleagues,19 and the Pettersen 
method20 was used as a sensitivity analysis.
Outcomes
The primary outcome measure was the absolute 
change in aortic root diameter per year, measured by 
transthoracic echocardiography. Secondary outcomes 
reported here were annual rate of change in the Z score 
of aortic root diameter, occurrence of clinical events 
including aortic dissection, surgery for aortic dilatation 
death, and the incidence of adverse and serious adverse 
events.16 Additionally, effects of irbesartan on systolic and 
diastolic blood pressure over the follow-up period are 
reported. TGF-β samples were obtained from a subset of 
patients who provided consent at baseline and 1 year. 
Samples were analysed by use of ELISA and full methods 
are provided in the appendix. Serious adverse events were 
reported by investigators on specific forms and reviewed 
by adjudicators blinded to treatment allocation. Reasons 
for study withdrawals and treat ment discontinuation and 
possible side-effects of treatment were also documented.
Statistical analysis
On the basis of existing information on aortic root 
dilatation in Marfan syndrome, the original sample size 
was set up to detect a 0·5 mm reduction in the aortic 
root diameter on irbesartan compared with placebo with 
an SD of 1·8 mm. 490 participants were anticipated to 
detect this difference, assuming up to a 20% drop-out rate 
and 80% power. Recruitment was slower than expected 
and trial recruitment was terminated at 192 participants. 
The loss of power was mitigated by extending follow-up 
to a maximum of 5 years and statistical analyses for 
the rate of aortic dilatation that accounted for repeated 
measurements and missing outcome data.
The primary analysis was the comparison of the change 
in aortic root diameter per year between the irbesartan 
and placebo groups. The population in the intention-to-
treat analysis for the primary and secon dary outcomes 
included all randomly assigned patients according to 
their original treatment allocation. An additional analysis 
of the primary outcome was repeated including patients 
only up to the point that they were known to have stopped 
taking the trial treatment (per-protocol analysis). The 
mean annual rate of aortic root dilatation in each 
treatment group and the absolute difference in these 
rates was estimated using a linear mixed effects model 
for repeated measures.21 This model accounts for the 
baseline measure of aortic root diameter, while also 
incorporating all follow-up measurements, and enables 
the inclusion of participants with missing measurements. 
The model used in the primary analysis assumes that 
aortic root diameter changes linearly over time and a 
sensitivity analysis that relaxes this assumption was also 
done as follows: at each timepoint (from 1 to 5 years), the 
Placebo, n=88 Irbesartan, n=104
Age (years)
6 to <11 19 (22%) 21 (20%)
11 to <18 26 (30%) 27 (26%)
18 to <25 13 (15%) 22 (21%)
25 to <41 30 (34%) 34 (33%)
Sex
Female 42 (48%) 57 (55%)
Male 46 (52%) 47 (45%)
Ethnicity
White British, Irish, or 
other
78 (89%) 97 (93%)
Asian 6 (7%) 2 (2%)
Black African or Caribbean 2 (2%) 1 (1%)
Mixed 1 (1%) 2 (2%)
Other 1 (1%) 2 (2%)
Aortic root diameter, mm 34·4 (5·8) 34·4 (5·5)
Aortic Z score 3·3 (2·1) 3·2 (2·0)
β-blocker use 52 (59%) 56 (54%)
Systolic blood pressure, 
mm Hg
109 (15)* 110 (16)
Diastolic blood pressure, 
mm Hg
64 (11)* 66 (12)
Heart rate 72 (13)* 72 (14)
Height, cm 178 (161–186) 175 (163–187)
Weight, kg 60·7 (44·6–73·1) 61·6 (44·0–76·8)
Body-mass index, kg/m² 18·9 (16·0–22·4) 19·3 (15·8–22·5)
Body surface area, m² 1·78 (1·50–1·96) 1·78 (1·44–2·01)
Lower segment, cm 94 (84–100)* 94 (86–100)
Arm span, cm 181 (164–190)† 179 (163–192)
Creatinine, μmol/L 56 (14)* 56 (16)*
Data are n (%), mean (SD), or median (IQR). *One patient with missing data. 
†Two patients with missing data.
Table 1: Baseline characteristics
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mean aortic root diameter in each treatment group, 
along with the absolute difference in these means, was 
estimated using a linear mixed effects model for repeated 
measures. This model accounts for the baseline measure 
of aortic root diameter.22 The model includes a continuous 
variable for time (in years), random intercepts and 
slopes, a linear interaction between time and treatment 
group, and assumes no effect of treatment at baseline. 
An unstructured variance-covariance matrix was used to 
allow for correlations between the random intercepts and 
slopes. The model was fitted using restricted maximum 
likelihood. Patients were followed for between 2 and 
5 years and like all linear mixed models, the model 
assumes that when data on aortic root diameter were 
missing, they were missing-at-random. Further details of 
the model are provided in the appendix (p 3).
Similar models were used to examine the effect of 
irbesartan compared with placebo on the annual rates of 
change in aortic diastolic diameter, aortic Z score and 
systolic and diastolic blood pressure, and differences in 
TGF-β at 1 year. A small number of prespecified sub-
group analyses were done for age, gender, blood pressure, 
β-blocker use, and aortic Z score by incorporating 
appropriate interaction terms. TGF-β was analysed in a 
subgroup of patients and was an exploratory post-hoc 
analysis. All statistical analyses were done on the 
intention-to-treat principle using Stata IC version 15.1.
This trial is registered with ISRCTN, number 
ISRCTN90011794.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of the report. The corresponding author had full access to 
all the data in the study and had final responsibility 
for the decision to submit for publication.
Results
Between March 14, 2012, and May 1, 2015, 192 participants 
were recruited; 104 were randomly assigned to 
irbesartan and 88 to placebo (figure 1). Participants 
were followed for a median of 4 years (IQR 3–5), with 
the final patient visit on March 12, 2018. Baseline 
characteristics were well balanced between the groups 
Placebo Irbesartan Difference (95% CI) p value
Change in aortic root systolic diameter, 
mm per year, mean (95% CI)
0·74 (0·60 to 0·89) 0·53 (0·39 to 0·67) –0·22 (–0·41 to –0·02) 0·030
Aortic root diameter, mm
Baseline, mean (SD), n 34·4 (5·8), 88 34·4 (5·5), 104 ·· ··
1 year, mean (95% CI), n 35·3 (34·4 to 36·1), 85 34·5 (33·6 to 35·3), 94 –0·82 (–1·33 to –0·30) 0·0017
2 years, mean (95% CI), n 35·9 (35·0 to 36·8), 77 35·2 (34·3 to 36·0), 85 –0·75 (–1·41 to –0·10) 0·024
3 years, mean (95% CI), n 36·5 (35·7 to 37·4), 71 35·9 (35·0 to 36·7), 79 –0·67 (–1·32 to –0·03) 0·041
4 years, mean (95% CI), n 37·1 (36·2 to 38·1), 57 36·2 (35·3 to 37·1), 57 –0·95 (–1·86 to –0·05) 0·038
5 years, mean (95% CI), n 39·2 (38·0 to 40·4), 29 37·8 (36·7 to 39·0), 29 –1·37 (–2·83 to 0·08) 0·065
Comparisons are made between groups at each timepoint. At the final follow-up visit the majority of patients had not reached 5 years of study participation, which accounts 
for the sharp decrease in numbers available for follow-up between year 4 and 5.
Table 2: Aortic root diameter
Figure 2: Aortic diameter measurements over time
(A) Mean aortic root diameter over time. (B) Mean aortic Z score over time. Means were estimated by use of a linear 
mixed effects model for repeated measures. At the final follow up visit the majority of patients had not reached 5 years 
of study participation, which accounts for the sharp decrease in numbers available for follow-up between year 4 and 5.
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(table 1); participants had a median age of 18 years 
(12–28), 99 (52%) were female, mean blood pressure 
was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) 
participants were taking β-blocker treatment at 
baseline. Of the 149 patients who agreed to fibrillin-1 
gene mutation analysis, 138 (93%) were confirmed as 
having positive mutations. More withdrawals occurred 
in the irbesartan group than in the placebo group, 
although they did not appear to be related to any side-
effects of treatment. Among the participants remaining 
in follow-up, discontinuation of study medication did 
not differ between the two groups (appendix p 5). A 
dose of 300 mg of irbesartan was achieved in 80% of 
partici pants with no apparent difference related to age 
or weight (appendix pp 5–6).
At baseline, mean aortic root diameter was 34·4 mm 
(SD 5·6; table 2). The annual rate of change in aortic 
root systolic diameter was lower in the irbesartan group 
than in the placebo group (0·53 mm per year [95% CI 
0·39 to 0·67] vs 0·74 mm per year [0·60 to 0·89]; 
difference in means –0·22 mm per year [–0·41 to –0·02], 
p=0·030). At 3 years the estimated difference in the 
mean aortic root diameters was –0·67 mm (95% CI 
–1·32 to –0·03, p=0·041; figure 2A; table 2). A similar 
finding was also apparent when diastolic diameters 
were used (0·62 mm per year [95% CI 0·49 to 0·76] in 
the irbesartan group vs 0·82 mm per year [0·68 to 0·96] 
in the placebo group; difference in means –0·20 mm 
per year [–0·39 to –0·01], p=0·038; appendix p 6). The 
per-protocol analysis based on measurements to the 
point that treatment was discontinued showed similar 
results to the intention-to-treat analysis (difference in 
means –0·21 mm per year, 95% CI –0·40 to –0·02, 
p=0·027).
The annual rate of change of aortic root Z scores was 
also lower in the irbesartan group (0·05 per year [95% CI 
–0·02 to 0·11] vs 0·15 per year [0·08 to 0·22]; difference 
in means –0·10 per year [–0·19 to –0·01], p=0·035; 
table 3). Results for mean rate of change in Z score for 
irbesartan com pared with placebo based on the Pettersen 
formula20 were very similar (–0·10 per year, 95% CI 
–0·18 to –0·01, p=0·028). At 3 years, the estimated 
difference in the mean aortic Z scores was –0·41 mm 
(95% CI –0·73 to –0·08, p=0·013; figure 2B; table 3).
There was no evidence for an interaction in any of 
the prespecified subgroup analyses. Specifically, there 
was no evidence of interaction with concurrent 
β blocker use. Irbesartan could have greater effects in 
younger participants and those with a higher aortic 
Z score at baseline, but no statistical evidence supported 
this (figure 3). TGF-β concentrations from baseline to 
1 year for 99 patients did not differ between groups 
(appendix p 7).
In the placebo group, both systolic and diastolic 
blood pressure consistently increased during the study, 
whereas blood pressure was reduced in the irbesartan 
group. The difference at 1 year (irbesartan compared with 
placebo) was –6·3 mm Hg (95% CI –9·8 to –2·9) in 
systolic blood pressure and –3·6 mm Hg (–6·5 to –0·8) 
in diastolic blood pressure which was maintained 
throughout the trial (appendix pp 8, 10).
The numbers of patients reporting at least one serious 
adverse event were 21 (24%) in the irbesartan group 
Placebo Irbesartan Difference (95% CI) p value
Change in aortic Z score (per year), 
mean (95% CI)
0·15 (0·08 to 0·22) 0·05 (–0·02 to 0·11) –0·10 (–0·19 to –0·01) 0·035
Aortic Z score
Baseline, mean (SD); n 3·28 (2·10); 88 3·21 (2·00); 104 ·· ··
1 year, mean (95% CI), n 3·44 (3·10 to 3·77), 84 2·96 (2·63 to 3·30), 93 –0·47 (–0·74 to –0·20) 0·0006
2 years, mean (95% CI), n 3·53 (3·16 to 3·90), 76 3·11 (2·75 to 3·47), 84 –0·42 (–0·74 to –0·10) 0·010
3 years, mean (95% CI), n 3·63 (3·26 to 4·00), 71 3·22 (2·86 to 3·59), 78 –0·41 (–0·73 to –0·08) 0·013
4 years, mean (95% CI), n 3·72 (3·30 to 4·14), 57 3·18 (2·76 to 3·60), 56 –0·54 (–0·98 to –0·10) 0·016
5 years, mean (95% CI), n 4·38 (3·80 to 4·97), 28 3·94 (3·35 to 4·52), 28 –0·45 (–1·14 to 0·25) 0·21
Comparisons are made between groups at each timepoint. At the final follow-up visit the majority of patients had not reached 5 years of study participation, which accounts 
for the sharp decrease in numbers available for follow-up between year 4 and 5.
Table 3: Aortic Z score
Figure 3: Differences in rate of aortic root diameter change
Difference in rates,
mm per year (95% CI)
Interaction
p value
Age
<18 years (n=93)
≥18 years (n=99)
Gender
Female (n=99)
Male (n=93)
β blocker use
Yes (n=108)
No (n=84)
Aortic Z score
<3 (n=93)
≥3 (n=99)
Overall (n=192)
 0·13
 0·51
 0·62
 0·07
–0·34 (–0·61 to –0·07)
–0·05 (–0·32 to 0·21)
–0·26 (–0·53 to 0·01)
–0·13 (–0·40 to 0·14)
–0·26 (–0·51 to 0·00)
–0·16 (–0·46 to 0·14)
–0·06 (–0·33 to 0·21)
–0·41 (–0·68 to –0·14)
–0·22 (–0·41 to –0·02)
0–1·0 0·5–0·5
Favours placeboFavours irbesartan
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and 24 (23%) in the placebo group. No differences 
in the occurrence of any serious adverse events, or 
those classified as cardiovascular, was observed between 
irbesartan and placebo (appendix pp 8–9). There were 
five aortic surgical procedures in the irbesartan group 
(two elective aortic root repairs and three elective external 
stent procedures) and four in the placebo group 
(three elective aortic root repairs and one emergency 
aortic dissection). There were no deaths during the trial.
Discussion
This study provides evidence of a reduction in the rate of 
aortic root dilatation in children and young adults with 
Marfan syndrome treated with irbesartan compared with 
placebo, over a 5-year observation period. The treatment 
was well tolerated, and no differences in adverse events 
due to suspected side-effects were observed between 
irbesartan and placebo groups.
The effects of irbesartan on reduction of aortic dilatation 
appear to occur early and to be maintained over time 
compared with placebo These effects are mirrored by 
effects on blood pressure, suggesting a possible associ-
ation. The apparent increase in aortic diameter after year 
4 in both groups might be an artifact due to the reduced 
numbers available for follow-up during that period, 
although the observed reduction in aortic root diameter 
in the irbesartan group remained.
Our study had a robust double-blind design with use of 
a placebo control, an independent core laboratory blinded 
to treatment to evaluate echocardiographic endpoints, 
high proportions of children, more than 50% treatment 
with β blockers and good compliance to trial treatment. 
We provide evidence of a reduction in the rate of aortic 
dilatation in participants receiving irbesartan that was 
apparent at 1 year and maintained for the duration of the 
study. In our cohort of both children and adults, we 
used the rate of change in the absolute diameter as the 
primary endpoint, because it was a more direct measure. 
Our findings were similar for measurements of diastolic 
aortic root diameter and Z score, which take somatic 
growth over time into account. There has been discussion 
about the most appropriate method to estimate Z score 
in the Marfan population.23 These methods for esti-
mating aortic Z score have been primarily developed 
and validated in a population that shows somatic 
growth and might not be reliable in adults. We used the 
Devereux method for the primary Z score analysis and 
the Pettersen method for sensitivity analysis, which 
yielded very similar results for differences in rate of 
change between irbesartan and placebo.
Previous randomised studies of ARBs in Marfan 
syndrome have all assessed the impact of losartan against 
either β blocker, placebo-control or open control.10–15 
Groenink and colleagues13 reported a beneficial effect of 
open label losartan over 3 years of about 0·2 mm per year 
which is similar to our finding. The study only included 
adults with established aortic root dilatation, in contrast 
to our study, in which half of all participants were 
younger than 18 years. Milleron and colleagues12 showed 
a modest, but not statistically significant, reduction in 
aortic dilatation with losartan compared with placebo 
in 303 patients with Marfan syndrome followed for 
3·5 years.
β blockers might not be tolerated in some Marfan 
patients with asthmatic symptoms and might para-
doxically worsen vascular stiffness.24 β blockers and ARBs 
are therefore not competitive and if effective, ARBs 
might be synergistic or additive to standard β-blocker 
therapy. In the US Pediatric Network Trial of losartan 
versus atenolol among 608 participants with Marfan 
syndrome aged 6 months to 25 years,10 the rate of aortic 
dilatation did not differ between the two groups. The 
Pediatric Heart Network Trial is the largest randomised 
controlled trial in Marfan syndrome and suggests that 
ARBs and β blockers might have similar effects on aortic 
dilatation.10 In the AIMS trial, β blockers were provided 
according to clinical need and about half the patients 
in each group were on β blockers at baseline. We used 
a placebo control rather than a β blocker, although 
β blockers were used according to clinical indication in 
more than half the patients. We found no evidence of 
interaction of irbesartan effect with β blockers or in any 
prespecified subgroup, although the study was under-
powered in this regard.
Unlike other studies, AIMS assessed the effects of 
irbesartan in Marfan syndrome. Irbesartan is a selective 
angiotensin type-1 receptor blocker with greater bioavail-
ability and a longer half-life than losartan (11–15 h for 
irbesartan vs 6–9 h for losartan), with more powerful 
antihypertensive effects.25,26 Irbesartan might also have 
effects on the pathophysiology of aortic disease, including 
TGF-β pathways.7 Another possibility is that effects on 
aortic dilatation reflect reduced blood pressure. Milleron 
and colleagues12 showed that losartan resulted in a similar 
reduction in systolic blood pressure compared with the 
control, as we observed in the AIMS trial, without a clear 
effect on the rate of aortic dilatation. This suggests other 
pathways might be involved in the clinical effect, although 
patients were also on average of 10 years older than those 
in this study. We also found a reduced rate of change of 
diastolic aortic diameter which is likely to be less 
dependent on ambient blood pressure. Subgroup analyses 
showed numerically greater reductions with irbesartan in 
younger participants and those with established aortic 
dilatation at baseline, but they were not statistically 
significant and will require confirmation in other studies. 
About 40% of patients contributed to TGF-β analysis, and 
the groups did not differ from baseline to 1 year. Effects on 
reducing aortic dilatation in Marfan syndrome might be a 
class effect among ARBs, and any differences observed 
across the trials might be related to patient selection, 
doses achieved, duration of treatment, and precision of 
measurement method, which will be further assessed in a 
planned individual patient data meta-analysis.27
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AIMS was neither designed nor powered to detect 
differences in clinical outcomes between the groups and 
the primary outcome of aortic diameter is a surrogate 
measure. In clinical practice, aortic diameter measured 
by echocardiography is usually used to determine the 
point at which surgical intervention is indicated, and we 
postulate that reduced rate of aortic dilatation with 
irbesartan might delay the need for surgery and improve 
outcomes, although the clinical effect of these modest 
differences remains unclear. Additionally, irbesartan 
was safe and well tolerated in both children and adults 
with no difference in the number of adverse events or 
withdrawals due to side effects between the two groups.
This study had some limitations. The trial was unable 
to enrol the original sample size of 490 participants. 
Extending follow-up and statistical analysis that used 
the correlations between baseline and follow-up 
measures improved the precision of the estimated 
treatment effects and helped to preserve power, although 
the smaller than planned sample size remains a 
limitation. This resulted in a SD of 0·53 mm per year 
for the rate of aortic dilatation, compared with the 
1·8 mm used to compare follow-up aortic root diameters 
in the original sample size estimation. By chance more 
participants were assigned to the irbesartan group due 
to stratification by centre, age, and β blocker use, the 
lower than planned sample size, and incomplete 
randomisation blocks because several centres enrolled 
only a few participants.
In summary, in this double-blind, placebo-controlled 
randomised controlled trial, we have shown that irbesartan 
can slow the rate of aortic dilatation in children and adults 
with Marfan syndrome and is well tolerated. The clinical 
implications of this observation need further investigation, 
but our data provide evidence to support the use of 
irbesartan to reduce the rate of aortic dilatation in this 
relatively common and potentially fatal inherited condition.
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